All listings for this product
Save on Non-Fiction Books
- AU $17.90Trending at AU $23.01
- AU $62.03Trending at AU $75.38
- AU $31.43Trending at AU $36.70
- AU $30.95Trending at AU $34.07
- AU $26.99Trending at AU $29.48
- AU $37.69Trending at AU $48.07
- AU $30.58Trending at AU $37.48
About this product
- DescriptionThe perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechlogy industry as escalating R&D costs are t being matched by increased output. Few observers doubt that selecting the right targets, ie those which are critical to disease pathology and are 'druggable', is the best starting point for improved productivity. The seven chapters of this volume describe recent progress towards drugs acting at a range of 'druggable' targets. One chapter addresses kinases, one covers an ion channel, two proteases are featured and three of the chapters cover G-protein coupled receptors, which has historically perhaps been the most fruitful area for medicinal chemists.
- Author BiographyDr Geoff Lawton has extensive experience in new medicine discovery across many therapeutic areas in both large and small companies and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was for five years the research member of a global therapy area strategy planning team for inflammatory diseases, aligning research with the clinical development and marketing parts of the business. From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines. Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number small and medium sized biotech companies, CROs, VCs, academic groups and medical research charities. Geoff serves on the Board of Antabio, a French biotech company developing tomorrow's antibacterial drugs. He is a founder of INMedD, a new medicines discovery social enterprise.
- PublisherElsevier Science & Technology
- Date of Publication25/04/2006
- SubjectIndustrial Chemistry & Manufacturing
- Series TitleProgress in Medicinal Chemistry
- Series Part/Volume Numberv. 44
- Place of PublicationOxford
- Country of PublicationUnited Kingdom
- ImprintElsevier Science Ltd
- Weight630 g
- Width210 mm
- Height280 mm
- Spine20 mm
- Edited byF. D. King,George Lawton
This item doesn't belong on this page.
Thanks, we'll look into this.